Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.35 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11894755 | 0.92 | MEN1 (0.38) | HTTGAAMEN1KMT2ALMNA | |
| SCHEMBL11894867 | 0.86 | KMT2A (0.35) | HTTGAAMEN1KMT2ALMNA | |
| SCHEMBL30958865 | 0.77 | MEN1 (0.39) | HTTMEN1KMT2ACKS1BSKP2 | |
| SCHEMBL11954834 | 0.75 | ABCB1 (0.40) | HTTGAASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL12960857 | 0.75 | KMT2A (0.34) | HTTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3631669 | 0.75 | ROCK2 (0.48) | MEN1KMT2AALDH1A1 | |
| SCHEMBL29527653 | 0.74 | CA12 (0.44) | HTTMEN1KMT2ALMNAMAPT | |
| SCHEMBL16694207 | 0.74 | MEN1 (0.42) | HTTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL17244833 | 0.73 | ABCB1 (0.38) | GAASMN1; SMN2LMNAMAPTTSHR | |
| SCHEMBL16018026 | 0.73 | CNR2 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006491-B2 | Structure and method for synthesizing and using dialkyl(2,4,6- or 2,6-alkoxyphenyl)phosphine and its tetrafluoroborate | ZHEJIANG UNIVERSITY (CN) | 2015-04-14 | — | — | US | disclosed |
| US-20120197030-A1 | STRUCTURE AND METHOD FOR SYNTHESIZING AND USING DIALKYL(2,4,6- OR 2,6-ALKOXYPHENYL)PHOSPHINE AND ITS TETRAFLUOROBORATE | ZHEJIANG UNIVERSITY (CN) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197030-A1 | STRUCTURE AND METHOD FOR SYNTHESIZING AND USING DIALKYL(2,4,6- OR 2,6-ALKOXYPHENYL)PHOSPHINE AND ITS TETRAFLUOROBORATE | PTK6, DCLK2, ERBB2 | HTT 3533/4885GAA 3105/4885SMN1; SMN2 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.